ArticleBiology direct2026
Piceatannol attenuates thoracic aortic aneurysm progression by targeting STK33.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThoracic aortic aneurysm (TAA) is a life-threatening vascular condition with limitedpharmacological interventions. This study aimed to identify novel causaldruggable genes and therapeutic candidates for TAA.
methodsWe performed Mendelian randomization (MR) by integrating cis-expression quantitativetrait loci (eQTL) and genome-wide association studies (GWAS) data to identifycausal genes for TAA. Therapeutic candidates were predicted via the DrugSignatures Database (DSigDB) and prioritized using molecular docking. Theclinical relevance of the lead target, STK33, was assessed in human TAA tissuesusing immunohistochemistry (IHC). The therapeutic efficacy of piceatannol wasrigorously validated across three distinct platforms: Angiotensin II(AngII)-stimulated vascular smooth muscle cells (VSMCs), and two complementaryanimal models (BAPN-induced and AngII-infused TAA mice).
resultsMR analysis identified 31 druggable genes significantly associated with TAA risk.Integration with DSigDB and molecular docking pinpointed piceatannol as a potentcandidate targeting STK33. IHC staining revealed that STK33 expression wasmarkedly downregulated in human TAA tissues, a trend consistently observed inAngII-stimulated VSMCs and mouse TAA models. In vivo, piceatannol treatmentsignificantly reduced TAA incidence, mortality, and aortic dilation in bothBAPN-induced and AngII-induced mouse models. Mechanistically, piceatannoleffectively restored STK33 protein levels and attenuated the loss of VSMCcontractile markers (MYH11, α-SMA, and CNN1) both in vivo and invitro. These protective effects were largely abolished by STK33 knockdown,confirming a target-specific mechanism.
conclusionsPiceatannol attenuates TAA progression, potentially through targeting and stabilizing STK33 expression. By utilizing a multi-model validation strategy (two in vivo modelsand an in vitro cell model), our findings highlight the piceatannol-STK33 axisas a promising therapeutic candidate for TAA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.